Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Spencer, Andrew; Lentzsch, Suzanne; Weisel, Katja; Avet‐Loiseau, Hervé; M. Mark, Tomer; Špıčka, Ivan; Masszi, Tamás; Lauri, Birgitta; Levin, Mark-David; Bosi, Alberto; Hungria, Vânia; Cavo, Michèle; Lee, Je‐Jung; K. Nooka, Ajay; Quach, Hang; Lee, Cindy; Barreto, Wolney; Corradini, Paolo; Min, Chang‐Ki; C. Scott, Emma; Chanan‐Khan, Asher; Horvath, Noemi; Capra, Marcelo; Beksaç, Meral; Ovilla, Roberto; Jo, Jae‐Cheol; Shin, Ho‐Jin; Sonneveld, Pieter; Soong, David; Casneuf, Tineke; Chiu, Christopher; Amin, Himal; Qi, Ming; Thiyagarajah, Piruntha; Kate Sasser, A.; M. Schecter, Jordan; Mateos, María‐Victoria

doi:10.3324/haematol.2018.194118

Public

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Published in Haematologica • Sep 20, 2018

Authors:

Andrew Spencer

Suzanne Lentzsch

Katja Weisel

Abstract

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma. A post hoc analysis ...

Subject

Daratumumab

Bortezomib

Dexamethasone

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!